Lonza will use TriLink's mRNA capping technology for treatment



SAN DIEGO – TriLink BioTechnologies, a subsidiary of Maravai LifeSciences (Nasdaq: MRVI), has entered into a licensing and supply agreement with Lonza, a major player in development and manufacturing for the pharmaceutical, biotechnology and nutritional industries.

The agreement announced today allows Lonza to develop mRNA therapeutics utilizing TriLink's proprietary CleanCap® mRNA capping technology.

CleanCap® technology has a capping efficiency of over 95% and is expected to simplify the mRNA production process, which is a significant improvement over traditional capping methods. This technology is particularly important as the use of mRNA as a therapeutic modality continues to increase, and TriLink's CleanCap® capping technology has been part of most approved mRNA and saRNA vaccines since its inception.

Under the terms of the agreement, TriLink will provide Lonza with a variety of CleanCap® cap analogues, including the recently launched CleanCap® M6, which increases mRNA expression by more than 30% compared to enzymatic capping methods.

These cap analogs will be used in Lonza's global mRNA development and manufacturing services, ranging from preclinical to Phase III programs.

Drew Burch, President of Nucleic Acid Manufacturing at TriLink, expressed enthusiasm for the collaboration and highlighted the potential of CleanCap® technology to accelerate programs from discovery to clinical stages.

Known for its expertise in nucleic acid and mRNA solutions, TriLink BioTechnologies provides high-quality materials and services to pharmaceutical and biotechnology companies. Its CleanCap® mRNA capping technology, one of its patented solutions, has played an important role in the rapid development and distribution of COVID-19 vaccines and is also used to treat a variety of diseases including oncology, infectious diseases and neurological diseases .

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

Maravai LifeSciences, TriLink's parent company, was recognized for its contributions to the life sciences industry by providing essential products for drug therapeutics, diagnostics and vaccine development.

The agreement, based on a press release, aims to further develop critical mRNA therapeutics by increasing access to advanced capping technologies.

Investment Professional Insights

In light of TriLink BioTechnologies' new agreement with Lonza, it's worth examining the financial health and market position of TriLink parent company Maravai LifeSciences (NASDAQ: MRVI ). According to the latest data from InvestingPro, Maravai LifeSciences has a market capitalization of approximately US$1.98 billion, demonstrating its strong influence in the life sciences industry. Despite a challenging market, the company has demonstrated strong returns over the past three months, with a total share price return of 35.34%, likely reflecting investor confidence in its growth trajectory and near-term business developments.

InvestingPro Tips indicates that Maravai LifeSciences has liquid assets that exceed its short-term debt, suggesting it has a solid financial foundation to support its operations and strategic initiatives, such as its recent licensing agreement. However, analysts have downgraded earnings for the period ahead and don't expect the company to make a profit this year. Additionally, Maravai LifeSciences is trading at a high valuation multiple of $15.89 million in EBITDA for the trailing 12 months to Q4 2023.

For investors seeking more in-depth analysis, Maravai LifeSciences also offers additional InvestingPro Tips, which can be accessed through a dedicated platform.Interested readers can use the discount code PRONEWS24 Get an additional 10% off with an annual or bi-annual subscription to Pro and Pro+, which includes comprehensive financial metrics and expert insights to inform investment decisions.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

This article was generated with the support of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *